Exicure, Inc. Announces 1-for-5 Reverse Stock Split
26 Août 2024 - 3:08PM
Business Wire
Exicure, Inc. (Nasdaq: XCUR, “the Company”) today announced that
it will effect a 1-for-5 reverse stock split of its outstanding
shares of common stock (the “Reverse Stock Split”). The Company
expects that the Reverse Stock Split will become effective at 5:00
pm on Tuesday, August 27, 2024, and its common stock will begin
trading on a split-adjusted basis at the open of trading on
Wednesday, August 28, 2024 under the new CUSIP number 30205M 309.
Exicure’s common stock will continue to trade on the NASDAQ Capital
Market under the symbol “XCUR”. The Reverse Stock Split is an
effort to regain compliance with Nasdaq’s listing rules.
The Reverse Stock Split was approved by the Company’s
stockholders at its Special Meeting of Stockholders held on August
20, 2024, to be effected by the Company’s Board of Directors within
approved parameters. The Company’s Board of Directors approved the
Reverse Stock Split at a ratio of 1-for-5 on August 20, 2024.
As a result of the Reverse Stock Split, each 5 shares of the
Company’s issued and outstanding common stock will be automatically
combined and converted into 1 issued and outstanding share of
common stock, resulting in the number of outstanding shares of
Exicure’s common stock being reduced from approximately 8.65
million to approximately 1.73 million immediately following the
effectiveness of the Reverse Stock Split. The Reverse Stock Split
will affect all holders of shares of our common stock uniformly and
each stockholder will hold the same percentage of our common stock
outstanding immediately following the reverse stock split as that
stockholder held immediately prior to the reverse stock split,
except for adjustments that may result from the treatment of
fractional shares as described below. The Reverse Stock Split will
not affect the number of authorized shares of common stock or the
par value of the common stock.
Stockholders holding their shares in book-entry form will not
need to take any action in connection with the Reverse Stock Split.
Stockholders will not receive fractional shares of common stock in
connection with the Reverse Stock Split. Instead, stockholders who
would have been entitled to a fractional share will receive such
additional fraction of a share of common stock as is necessary to
increase the fractional share to which they were entitled to a full
share.
Additional information on the Reverse Stock Split can be found
in the Company’s definitive proxy statement filed with the
Securities and Exchange Commission on July 30, 2024, which is
available on the SEC’s website at www.sec.gov and on the Company’s
website, www.exicuretx.com.
About Exicure, Inc.
Exicure, Inc. has historically been an early-stage biotechnology
company focused on developing nucleic acid therapies targeting
ribonucleic acid against validated targets. Following its recent
restructuring and suspension of clinical and development
activities, the Company is exploring strategic alternatives to
maximize stockholder value, both with respect to its historical
biotechnology assets and more broadly. For further information, see
www.exicuretx.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. There can be no
assurance regarding our ability to comply with the Panel’s decision
and the applicable listing criteria by the deadline or thereafter.
Forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause actual outcomes to
differ materially from the outcomes expressed or implied by this
report. Such risks include, among others, the possibility we will
not be able to cure existing listing deficiencies, the possibility
of additional deficiencies, the risk that the Company may not
adequately comply with the terms of the Panel’s decision, and the
risk that Nasdaq will ultimately delist the Company’s common stock.
All such factors are difficult to predict and may be beyond the
Company’s control. The Company undertakes no obligation and does
not intend to update or revise any forward-looking statements
contained herein, except as required by law or regulation. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this report.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240826933740/en/
Josh Miller 847-673-1700 media@exicuretx.com
Exicure (NASDAQ:XCUR)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Exicure (NASDAQ:XCUR)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024